Nothing Special   »   [go: up one dir, main page]

BR112022021321A2 - Formas cristalinas do composto de ftalazinona. - Google Patents

Formas cristalinas do composto de ftalazinona.

Info

Publication number
BR112022021321A2
BR112022021321A2 BR112022021321A BR112022021321A BR112022021321A2 BR 112022021321 A2 BR112022021321 A2 BR 112022021321A2 BR 112022021321 A BR112022021321 A BR 112022021321A BR 112022021321 A BR112022021321 A BR 112022021321A BR 112022021321 A2 BR112022021321 A2 BR 112022021321A2
Authority
BR
Brazil
Prior art keywords
crystalline forms
phthalazinone compound
phthalazinone
compound
cyclopropylamino
Prior art date
Application number
BR112022021321A
Other languages
English (en)
Inventor
Lee Kunhee
Lee Seoktaek
Ryu Keuncheol
Seo Hanna
YANG Hyeran
SEONG Wonje
Yoon Jinyoung
Original Assignee
Idience Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idience Co Ltd filed Critical Idience Co Ltd
Publication of BR112022021321A2 publication Critical patent/BR112022021321A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

FORMAS CRISTALINAS DO COMPOSTO DE FTALAZINONA. O presente relatório descritivo apresenta formas cristalinas de 4-[3-(3-[(ciclopropilamino)metil]azetidina-1-carbonil)-4-fluorobenzil]ftalazina-1(2H)-ona hidrocloreto, seus métodos de preparação e suas composições farmacêuticas.
BR112022021321A 2020-04-21 2020-04-24 Formas cristalinas do composto de ftalazinona. BR112022021321A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063013276P 2020-04-21 2020-04-21
PCT/IB2020/000324 WO2021214503A1 (en) 2020-04-21 2020-04-24 Crystalline forms of phthacaz1nonf compound

Publications (1)

Publication Number Publication Date
BR112022021321A2 true BR112022021321A2 (pt) 2022-12-20

Family

ID=78081129

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021321A BR112022021321A2 (pt) 2020-04-21 2020-04-24 Formas cristalinas do composto de ftalazinona.

Country Status (13)

Country Link
US (2) US11390608B2 (pt)
EP (1) EP4139297A4 (pt)
JP (1) JP2023537550A (pt)
KR (1) KR20230004723A (pt)
CN (1) CN115702151A (pt)
AR (1) AR121289A1 (pt)
AU (1) AU2020444056A1 (pt)
BR (1) BR112022021321A2 (pt)
CA (1) CA3176219A1 (pt)
IL (1) IL297464A (pt)
MX (1) MX2022013304A (pt)
TW (1) TW202140456A (pt)
WO (1) WO2021214503A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024009168A (es) * 2022-01-25 2024-08-09 Idience Co Ltd Composicion farmaceutica que incluye derivado de ftalazinona para coadministracion con farmaco antineoplasico.

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036576A1 (en) 2000-10-30 2002-05-10 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
PL1633724T3 (pl) 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0610680D0 (en) 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
CA2652167A1 (en) 2006-05-31 2007-12-06 Philip Jones Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase (parp)
PL2698062T3 (pl) 2006-12-28 2015-12-31 Abbvie Inc Inhibitory polimerazy poli(adp-rybozy)
ES2524787T3 (es) 2007-11-15 2014-12-12 Msd Italia S.R.L. Derivados de piridazinona como inhibidores de PARP
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
GB0804755D0 (en) 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
US8871765B2 (en) 2010-07-27 2014-10-28 Cadila Healthcare Limited Substituted 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one derivatives as poly (ADP-ribose) polymerase-1 inhibitors
CN102372706A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CN102372716A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CN102372698A (zh) 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
KR101528688B1 (ko) * 2010-12-02 2015-06-12 상하이 드 노보 파마테크 컴퍼니 리미티드 헤테로사이클릭 유도체, 이의 제조 방법 및 이의 의학적 용도
CN102485721B (zh) 2010-12-03 2015-12-09 曹亚 取代的2,3-二氮杂萘酮化合物及其用途
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
KR101670126B1 (ko) * 2013-09-13 2016-10-27 일동제약(주) 신규 프탈라지논 유도체 및 그 제조방법
KR20170037116A (ko) * 2015-09-25 2017-04-04 일동제약(주) 플루오로기가 치환된 프탈라지논 유도체 및 그 제조방법
WO2017191650A1 (en) * 2016-05-03 2017-11-09 Msn Laboratories Private Limited Process for the preparation of 5-[[[(2s)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1s)-1-(4-phenyl-1h-imidazol-2-yl)ethyl]amino]methyl-2-methoxybenzoic acid and its polymorphs thereof

Also Published As

Publication number Publication date
US11390608B2 (en) 2022-07-19
US20210323945A1 (en) 2021-10-21
EP4139297A1 (en) 2023-03-01
AR121289A1 (es) 2022-05-04
AU2020444056A1 (en) 2022-11-17
IL297464A (en) 2022-12-01
US20220372020A1 (en) 2022-11-24
JP2023537550A (ja) 2023-09-04
EP4139297A4 (en) 2024-05-22
WO2021214503A1 (en) 2021-10-28
TW202140456A (zh) 2021-11-01
CA3176219A1 (en) 2021-10-28
KR20230004723A (ko) 2023-01-06
US11691964B2 (en) 2023-07-04
MX2022013304A (es) 2022-12-15
CN115702151A (zh) 2023-02-14

Similar Documents

Publication Publication Date Title
PH12019502037A1 (en) Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
PH12021551167A1 (en) New heterocyclic compounds
NO20073956L (no) Pyrazolderivater for inhibering av CDK og GSK
NO20062894L (no) 6-alkenyl og 6-fenylalkylsubstituert 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)polymeraseinhibitorer
NO20070532L (no) Substituerte 2-alkyl-kinazolinonderivater som PARP-inhibitorer
NO20071843L (no) Substituerte anilinderivater
NO20070529L (no) Kinazolindionderivater som parp-inhibitorer
NO20062136L (no) Imidazopyrazintyrosin-kinaseinhibitorer
UY3975U (es) Pestillo empotrable con ajuste rotacional
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
BR112022021321A2 (pt) Formas cristalinas do composto de ftalazinona.
WO2007103839A3 (en) Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors
PH12019501068A1 (en) Crystalline forms of a magl inhibitor
BRPI0618589B8 (pt) composto de oxazol, composição farmacêutica compreendendo o referido composto, processos de fabricação e usos dos mesmos
NO20063028L (no) 6-substituerte 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)-polymeraseinhibitorer
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
NO20076066L (no) Oksadiazolderivater som DGAT-inhibitorer
EA200970019A1 (ru) Кристаллические формы 4-[2-(4-метилфенилсульфанил)фенил]пиперидина с объединенным ингибированием повторного поглощения серотонина и норадреналина для лечения невропатической боли
NO20070564L (no) Kinoliner uten tiazolinonsubstituenter.
CR20220004A (es) Nuevos compuestos heterocíclicos
PH12021550687A1 (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt
MX2021003083A (es) Formas cristalinas de un agonista del receptor de farnesoide x.
CO2021005141A2 (es) Formas cristalinas sólidas de n-(1-((2-(dimetilamino)etil)amino)-2-metil-1-oxopropano-2-il)-4-(4-(2-metil-5-((2s,3r,4r,5s,6r)-3,4,5-trihidroxi-6-(metiltio)tetrahidro-2h-pirano-2-il)bencil)fenil)butanamida y métodos para su síntesis
EA201070781A1 (ru) Производные оксадиазола, активные на сфингозин-1-фосфате (s1p)
PE20211283A1 (es) Compuesto de 1,3,4-oxadiazolona y farmaco

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: VIDE PARECER..